[Corrections] Correction to Lancet Oncol 2018; 19: 474 –85

De Placido S, Gallo C, De Laurentiis M, et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol 2018; 19: 474 –85—In the authors' list, Carmen Mocerino should have been Carmela Mocerino. This correction has been made to the online version as of March 28, 2018, and the printed version is correct. Additionally, the supplementary appendix of this Article has been corrected as of March 28, 2018.
Source: The Lancet Oncology - Category: Cancer & Oncology Tags: Corrections Source Type: research